Abstract

BackgroundXpert MTB/RIF (Xpert) is being widely adopted in high TB burden countries. Analysis is needed to guide the placement of devices within health systems to optimize the tuberculosis (TB) case detection rate (CDR).MethodsWe used epidemiological and operational data from Uganda (139 sites serving 87,600 individuals tested for TB) to perform a model-based comparison of the following placement strategies for Xpert devices: 1) Health center level (sites ranked by size from national referral hospitals to health care level III centers), 2) Smear volume (sites ranked from highest to lowest volume of smear microscopy testing), 3) Antiretroviral therapy (ART) volume (sites ranked from greatest to least patients on ART), 4) External equality assessment (EQA) performance (sites ranked from worst to best smear microscopy performance) and 5) TB prevalence (sites ranked from highest to lowest). We compared two clinical algorithms, one where Xpert was used only for smear microscopy negative samples versus another replacing smear microscopy. The primary outcome was TB CDR; secondary outcomes were detection of multi-drug resistant TB, number of sites requiring device placement to achieve specified rollout coverage, and cost.ResultsPlacement strategies that prioritized sites with higher TB prevalence maximized CDR, with an incremental rate of 6.2–12.6% compared to status quo (microscopy alone). Diagnosis of MDR-TB was greatest in the TB Prevalence strategy when Xpert was used in place of smear microscopy. While initial implementation costs were lowest in the Smear Volume strategy, cost per additional TB case detected was lowest in the TB prevalence strategy.ConclusionIn Uganda, placement of Xpert devices in sites with high TB prevalence yielded the highest TB CDR at the lowest cost per additional case diagnosed. These results represent novel use of program level data to inform the optimal placement of new technology in resource-constrained settings.

Highlights

  • Tuberculosis (TB) remains a major global public health challenge, causing substantial morbidity and mortality [1]

  • We used epidemiological and operational data from Uganda (139 sites serving 87,600 individuals tested for TB) to perform a model-based comparison of the following placement strategies for Xpert devices: 1) Health center level, 2) Smear volume, 3) Antiretroviral therapy (ART) volume, 4) External equality assessment (EQA) performance and 5) TB prevalence

  • Placement strategies that prioritized sites with higher TB prevalence maximized case detection rate (CDR), with an incremental rate of 6.2–12.6% compared to status quo

Read more

Summary

Introduction

Tuberculosis (TB) remains a major global public health challenge, causing substantial morbidity and mortality [1]. The introduction of the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) represents the first true “game-changer” in the field of TB diagnostics in decades due to improved sensitivity, ease of use, and rapid turn-around-time of results made possible by the molecular platform, and in 2010, the World Health Organization endorsed the use of the Xpert device [2, 3]. It has been recommended that public health decision-makers utilize data from such technical studies and registration trials, and examine the existing epidemiology, health care infrastructure and clinical practice to optimize implementation and scale up [9]. Analysis is needed to guide the placement of devices within health systems to optimize the tuberculosis (TB) case detection rate (CDR)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call